Vol. 1 No. 9 (2021): September
Reimbursement Reviews

Durvalumab (Imfinzi)

Published September 7, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Durvalumab (Imfinzi) concentrate for solution for infusion, 50 mg/mL, IV.
  • Indication: First-line treatment of adult patients with extensive-stage small cell lung cancer, in combination with etoposide and either carboplatin or cisplatin